“Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated With Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials”. 2022. SKIN The Journal of Cutaneous Medicine 6 (2): s1. https://doi.org/10.25251/skin.6.supp.1.